Evidence map›Paper›PMID 32325695›Full record

ArticleMolecules (Basel, Switzerland)2020

Synthesis and Evaluation of [

Martha Sahylí Ortega Pijeira, Paulo Sérgio Gonçalves Nunes, Sofia Nascimento Dos Santos, Zhengxing Zhang, Arian Pérez Nario, Efrain Araujo Perini, Walter Miguel Turato, Zalua Rodríguez Riera, Roger Chammas, Philip H Elsinga and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Radiotracers for Molecular Imaging of Angiotensin-Converting Enzyme 2.International journal of molecular sciences · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Martha Sahylí Ortega PijeiraRadiopharmacy Center, Nuclear and Energy Research Institute (IPEN/CNEN-SP), CEP 05508-000 São Paulo, Brazil.
Paulo Sérgio Gonçalves NunesSchool of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo (FCFRP-USP), CEP 14040-903 Ribeirão Preto, Brazil.
Sofia Nascimento Dos SantosRadiopharmacy Center, Nuclear and Energy Research Institute (IPEN/CNEN-SP), CEP 05508-000 São Paulo, Brazil.
Zhengxing ZhangDepartment of Molecular Oncology, BC Cancer Research Centre, Vancouver, BC V5Z 1L3, Canada.
Arian Pérez NarioRadiopharmacy Center, Nuclear and Energy Research Institute (IPEN/CNEN-SP), CEP 05508-000 São Paulo, Brazil.
Efrain Araujo PeriniRadiopharmacy Center, Nuclear and Energy Research Institute (IPEN/CNEN-SP), CEP 05508-000 São Paulo, Brazil.
Walter Miguel TuratoSchool of Pharmaceutical Sciences-University of São Paulo-USP, CEP 05508-000 São Paulo, Brazil.
Zalua Rodríguez RieraDepartamento de Radioquímica, Instituto Superior de Tecnologías y Ciencias Aplicadas (InSTEC), Universidad de La Habana, CP 10400 La Habana, Cuba.
Roger ChammasDepartment of Radiology and Oncology, Faculty of Medicine, University of São Paulo, CEP 01246903 São Paulo, Brazil.ORCID 0000-0003-0342-8726
Philip H ElsingaDepartment of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Internal Post code: EB79, PO box 30.001, 9700 RB Groningen, The Netherlands.
Kuo-Shyan LinDepartment of Molecular Oncology, BC Cancer Research Centre, Vancouver, BC V5Z 1L3, Canada.ORCID 0000-0002-0739-0780
Ivone CarvalhoSchool of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo (FCFRP-USP), CEP 14040-903 Ribeirão Preto, Brazil.
Emerson Soares BernardesRadiopharmacy Center, Nuclear and Energy Research Institute (IPEN/CNEN-SP), CEP 05508-000 São Paulo, Brazil.
National Nuclear Energy Commission · BRUniversidade de Ribeirão Preto · BRUniversidade de São Paulo · BRHigher Institute of Technologies and Applied Sciences · CUUniversity Medical Center Groningen · NL

Funding

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 001Emerging Leaders in the Americas Program (ELAP) 2016-2017Fundação de Amparo à Pesquisa do Estado de São Paulo 2012/06875-6
6 · The paper itself

Abstract

Losartan is widely used in clinics to treat cardiovascular related diseases by selectively blocking the angiotensin II type 1 receptors (AT

Indexed as

Fluorine RadioisotopesMolecular ImagingAnimalsLosartanMiceModels, AnimalMolecular StructurePositron-Emission TomographyProtein BindingRadiopharmaceuticalsReceptor, Angiotensin, Type 1Tissue DistributionFluorine-18Fluorine RadioisotopesLosartanRadiopharmaceuticalsReceptor, Angiotensin, Type 118F-19F isotopic exchange approach[18F]AMBF3Los[18F]FEtLos[18F]Fluoroethylationammoniomethyltrifluoroborate-losartanangiotensin II type 1 receptorsfluoroethyl-losartanin vitro assaysrenal autoradiographyµPET imaging

Identifiers

PMID32325695
PMCPMC7221519
OpenAlexW3016439079

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.